ADAG
Adagene, Inc.
NASDAQ · Healthcare · Biotechnology · CN
$2.29
+11.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +109.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.2%
- EBITDA
- +46.8%
- EBIT
- +40.4%
- Net income
- +47.3%
- EPS
- +51.6%
- Free cash flow
- +47.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026